COVID-19:Nichiiko增产Futhan(nafamostat):向Latus Therapeutics提供

COVID-19:Nichiiko增产Futhan(nafamostat):向Latus Therapeutics提供

Nichiiko:

在5月18日举行的财务结果发布会上,该公司宣布将增加日清公司用于急性胰腺炎的药物Futhan的生产。

Futhan(纳法莫司):

有望成为新的冠状病毒感染的候选者之一。

将来,我们决定在爱知工厂进行资本投资。

旨在于2021年1月开始运营,该系统的年产量为100万件。

复山临床试验:

它是Nichiiko从Torii Pharmaceutical继承而来的长期上市产品,目前的处方量为每年60万至70万瓶。

2020年3月,东京大学研究小组作了演讲,表明其对新型冠状病毒的功效。

复星将免费提供给全球正在进行的临床研究。

日本:东京大学

我们正在与东京大学医院和国家全球健康与医学中心(NCGM)合作促进特定的临床研究。

英国:Latus Therapeutics

牛津大学和爱丁堡大学发起了一项合作研究,以评估疗效。

Nichi-Iko捐赠必要的Futhan。

化学日报

https://www.chemicaldaily.co.jp/

新闻发布|东京大学医院

〜“ Fabiravir和甲磺酸萘法莫他联合治疗COVID-19肺炎的患者”〜

开始进行多中心,单盲,随机对照试验(特定临床研究)

东京大学医院

针对SARS-CoV-2阳性的肺炎患者,
含favipiravir(Abigan®Tablets 200mg)
甲磺酸萘法莫他(Futhan®50注射剂)
联合疗法的具体临床研究已经开始。

该测试将与东京大学医院及其他机构合作进行。

https://www.h.u-tokyo.ac.jp/press/20200508.html

News | Latus Therapeutics

Latus Therapeutics is leading a joint research team of scientists from the University of Oxford and the University of Edinburgh.

The trial

aims to evaluate the effectiveness for the treatment of COVID-19 of

Nafamostat Mesilate (brand name: Futhan),

an existing medicine for other indications in Japan. Nichi-Iko Pharmaceutical Co., Ltd, Japan-based leading drug manufacturer,

has generously donated supplies of Nafamostat for the initial clinical evaluation.

This crucial research

will utilise an existing medicine that has previously been shown to prevent the virus from infecting human cells in the laboratory.

Unlike vaccine treatments, which will take time to develop, this drug could be used immediately to fight COVID-19, having safely been used in Japan for 35 years to treat pancreatitis.

Studies have shown that

the drug blocks virus entry into lung cells and prevents it from multiplying in the human body. In this way we hope it will reduce the severity of disease in infected individuals.

This study is being supported

by a grant from the medical research charity LifeArc as part of its activity to address the need for new therapies for COVID-19.

https://www.latus-tx.com/news